Synthes partners with Kuros Biosurgery to develop biomaterials for spinal applications

Kuros and Synthes, Inc. Announce License and Development Agreement (press release)
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactivebiomaterial combination  products for trauma, wound and spinal indications has signed a license and development agreement with Synthes, Inc. a leading global medical device company.
Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros’ synthetic matrix technology in certain fields. Commenting on today’s announcement, Mr. Didier Cowling, CEO of Kuros, said: “We are del...